RxDoctor Payments Data

Kathryn Campion

Acute Care · Baltimore, MDNPI 1659992386

Payments from drug & device makers

$739in general payments, 2019–2025

Across 21 payments — averaging $35.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$266
  • Johnson & Johnson$189
  • Janssen Scientific Affairs, LLC$72
  • Bayer$55
  • Gilead$44
  • Tersera Therapeutics LLC$28
  • plus $85 from 4 others

What the payments were for

  • Food & beverage$739100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$739 in reported general payments places this provider in the 70th percentile of 502 acute care providers in Maryland.

See all acute care providers in Maryland

Medicare billing

Part B allowed, 2024
$55,112
Medicare patients
249
Services billed
701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide31$531,642
PomalystPomalidomide14$313,953
EliquisApixaban40$32,660
XareltoRivaroxaban18$22,059
Acyclovir219$6,167
ValacyclovirValacyclovir Hcl57$4,009
Colesevelam Hcl33$3,741
Cholestyramine LightCholestyramine23$2,043
Dexamethasone148$1,857
Oxycodone Hcl63$1,018
Gabapentin38$908
Potassium Chloride28$642
Duloxetine Hcl15$611
PrevaliteCholestyramine11$387
Tramadol Hcl23$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$23$313,95314 claims
Johnson & JohnsonXarelto$189$22,05918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 502 acute care providers in Maryland.

Other acute care in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →